Showing results (1191-1200 of 1,893) with videos related to

Sort By:
Pageof 190
Immunotherapy|January 24, 2024
Established and emerging biomarkers of immunotherapy in renal cell carcinomaYash Jani, Caroline S Jansen, Margo B Gerke, et al.
Immunotherapy|August 19, 2024
Fulminant immune-related colitis after dual checkpoint inhibitor therapy: case reportRobert Lukin, Aaron Ciner
Immunotherapy|June 18, 2024
Association between specific human leukocyte antigen alleles and development of thyroid immune-related adverse eventEisaku Sasaki, Yutaka Natori, Emi Tokuda, et al.
Immunotherapy|July 9, 2024
Sarcoidosis-like reactions in metastatic renal cell carcinoma patients treated with immune-based combinationsMimma Rizzo, Gaetano Pezzicoli, Carlo Ganini, et al.
Immunotherapy|August 16, 2023
Lichenoid dermatitis following PD-1 inhibitor-induced toxic epidermal necrolysis: a case report and literature reviewLong Zhang, Liang Wang, Qionghui Cheng, et al.
Immunotherapy|August 16, 2023
CACNA1C mutation as a prognosis predictor of immune checkpoint inhibitor in skin cutaneous melanomaYushan Huang, Anqi Lin, Tianqi Gu, et al.
Immunotherapy|October 25, 2023
The development of litifilimab (BIIB 059) for cutaneous and systemic lupus erythematosusYoung Min Cho, Richard Furie
Immunotherapy|July 19, 2023
Pembrolizumab plus chemotherapy for advanced non-small-cell lung cancer without tumor PD-L1 expression in AsiaYing Cheng, James Chih-Hsin Yang, Isamu Okamoto, et al.
Immunotherapy|July 11, 2023
An assessment of extended pembrolizumab dosing in advanced non-small-cell lung cancer in the COVID-19 pandemicGordon Taylor Moffat, Lilian Hanna, Wilma Hopman, et al.
Immunotherapy|July 4, 2023
Cost-effectiveness analysis of serplulimab as first-line treatment for advanced esophageal squamous cell carcinomaZhiwei Zheng, Ling Fang, Hongfu Cai, et al.
Pageof 190